help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rayner, T. E.
Right arrow Articles by Oliver, J. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rayner, T. E.
Right arrow Articles by Oliver, J. R.

Endocrinology, Vol 133, 1108-1115, Copyright © 1993 by Endocrine Society

ARTICLES

Prostaglandin F2 alpha mediates platelet-activating factor-stimulated atrial natriuretic factor release from the isolated rat heart

TE Rayner, BN Chen, JW McLoughlin, MF Menadue, RJ Norman and JR Oliver
Department of Medicine, Flinders Medical Centre, Bedford Park, South Australia.

Platelet-activating factor (PAF) and the prostaglandins have recently been shown to stimulate atrial natriuretic factor (ANF) secretion from the heart. As PAF also potentiates the release of cyclooxygenase products from isolated hearts, the role of these substances in PAF- induced ANF secretion was investigated. Using an isolated perfused rat heart preparation, cyclooxygenase inhibition by indomethacin or meclofenamic acid (10 microM for each) significantly attenuated the rise in ANF associated with PAF administration (2.5 nmol). Prostaglandin F2 alpha (PGF) produced an immediate and dose-dependent increase in ANF secretion, which was significant at 0.01 mumol and reached 348 +/- 66% over baseline values after a 1-mumol injection. Prostaglandin E2 (PGE) generated a much smaller 98 +/- 25% increase after a 1-mumol administration. Furthermore, PGF but not PGE was released from isolated hearts immediately after PAF administration. PGF release reached a maximum of 0.06 nmol/min g Heart-1 1 min after PAF stimulation and had returned to undetectable baseline values by 6 min. Cyclooxygenase inhibition abolished the release of PGF after PAF, in addition to attenuating (by 60-70%) the increased secretion of ANF after PAF injection. These results demonstrate very clearly that PGF is the major mediator for PAF-stimulated ANF secretion. Such an interaction may provide an alternative mechanism to atrial distension for the secretion of ANF in pathologies such as myocardial infarction, where autacoids such as PAF and the PGs are released from damaged cardiac muscle and elevated plasma levels of ANF are observed.


This article has been cited by other articles:


Home page
 Cardiovasc ResHome page
J. R. Dietz
Mechanisms of atrial natriuretic peptide secretion from the atrium
Cardiovasc Res, October 1, 2005; 68(1): 8 - 17.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. Rev.Home page
G. Montrucchio, G. Alloatti, and G. Camussi
Role of Platelet-Activating Factor in Cardiovascular Pathophysiology
Physiol Rev, October 1, 2000; 80(4): 1669 - 1699.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
S. Fong Yew, K. A. Reeves, and B. Woodward
Effects of prostaglandin F2{alpha} on intracellular pH, intracellular calcium, cell shortening and L-type calcium currents in rat myocytes
Cardiovasc Res, December 1, 1998; 40(3): 538 - 545.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1993 by The Endocrine Society